Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Bloom Burton to “Hold”

Bloom Burton downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a moderate buy rating to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other analysts have also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $15.00 price target (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $16.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $14.45 on Wednesday. The business’s 50 day simple moving average is $12.19 and its 200 day simple moving average is $10.09. Aurinia Pharmaceuticals has a one year low of $6.55 and a one year high of $16.20. The stock has a market capitalization of $1.90 billion, a PE ratio of 33.61 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. State of Wyoming raised its position in shares of Aurinia Pharmaceuticals by 33.2% during the third quarter. State of Wyoming now owns 37,702 shares of the biotechnology company’s stock worth $417,000 after purchasing an additional 9,396 shares during the period. Principal Financial Group Inc. raised its position in shares of Aurinia Pharmaceuticals by 6.7% during the third quarter. Principal Financial Group Inc. now owns 80,740 shares of the biotechnology company’s stock worth $892,000 after purchasing an additional 5,074 shares during the period. Thrivent Financial for Lutherans acquired a new position in shares of Aurinia Pharmaceuticals during the third quarter worth approximately $291,000. Vanguard Personalized Indexing Management LLC raised its position in Aurinia Pharmaceuticals by 27.2% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 13,892 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 2,973 shares during the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at $934,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.